Today, we shared the topline results from our Phase 3 PHOENIX trial. Read more in our press release:
bit.ly/3TbILMC
On behalf of the entire Amylyx team, we are grateful to the ALS community and for the dedication of trial participants, investigators, and study site teams. With data collected from 664 participants in PHOENIX, we are certain there will be important learnings that will help inform future ALS research.